172 related articles for article (PubMed ID: 27057638)
21. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Rose DB; Nellesen D; Neary MP; Cai B
J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
[TBL] [Abstract][Full Text] [Related]
22. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Kulke MH; Siu LL; Tepper JE; Fisher G; Jaffe D; Haller DG; Ellis LM; Benedetti JK; Bergsland EK; Hobday TJ; Van Cutsem E; Pingpank J; Oberg K; Cohen SJ; Posner MC; Yao JC
J Clin Oncol; 2011 Mar; 29(7):934-43. PubMed ID: 21263089
[TBL] [Abstract][Full Text] [Related]
23. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
24. Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.
Bajetta E; Catena L; Pusceddu S; Spada F; Iannacone C; Sarno I; Di Menna G; Dottorini L; Marte AM
Neuroendocrinology; 2018; 106(4):307-311. PubMed ID: 28743120
[TBL] [Abstract][Full Text] [Related]
25. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Abdel-Rahman O; Fouad M
Future Oncol; 2015; 11(8):1275-90. PubMed ID: 25832882
[TBL] [Abstract][Full Text] [Related]
27. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
Dimou A; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.
Yao JC; Lagunes DR; Kulke MH
Oncologist; 2013; 18(5):525-32. PubMed ID: 23615698
[TBL] [Abstract][Full Text] [Related]
29. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
30. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
32. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
Singh S; Carnaghi C; Buzzoni R; Pommier RF; Raderer M; Tomasek J; Lahner H; Valle JW; Voi M; Bubuteishvili-Pacaud L; Lincy J; Wolin E; Okita N; Libutti SK; Oh DY; Kulke M; Strosberg J; Yao JC; Pavel ME; Fazio N;
Neuroendocrinology; 2018; 106(3):211-220. PubMed ID: 28554173
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
34. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
Pusceddu S; Verzoni E; Prinzi N; Mennitto A; Femia D; Grassi P; Concas L; Vernieri C; Lo Russo G; Procopio G
Ther Adv Med Oncol; 2017 Mar; 9(3):183-188. PubMed ID: 28344663
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
36. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
37. [Mid gut neuroendocrine tumors: News on medical treatment].
Dior M; Dreanic J; Prieux-Klotz C; Brieau B; Brezault C; Coriat R
Presse Med; 2017 Jan; 46(1):4-10. PubMed ID: 28089247
[TBL] [Abstract][Full Text] [Related]
38. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
39. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
40. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.
Yao J; Garg A; Chen D; Capdevila J; Engstrom P; Pommier R; Van Cutsem E; Singh S; Fazio N; He W; Riester M; Patel P; Voi M; Morrissey M; Pavel M; Kulke MH
Endocr Relat Cancer; 2019 Apr; 26(4):391-403. PubMed ID: 30667365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]